deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT05221320

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ)

Sponsor: BioMed Valley Discoveries, Inc

Updated 16 times since 2022 Last updated: Sep 5, 2025 Started: May 26, 2022 Primary completion: May 8, 2024 Completion: Jul 14, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of Enrollment for Remaining Open Baskets

This PHASE2 trial investigates Gastrointestinal Cancer and Tumor, Solid and is currently terminated or withdrawn. BioMed Valley Discoveries, Inc leads this study, which shows 16 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Mar 2024 · 9 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

16 versions recorded
  1. Oct 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE2

    Status: RecruitingTerminated

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

Show 11 earlier versions
  1. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Jun 2023 — Mar 2024 [monthly]

    Recruiting PHASE2

  3. Feb 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  4. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  6. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  7. Oct 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  8. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

  9. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  10. Apr 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE2

  11. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioMed Valley Discoveries, Inc
Data source: BioMed Valley Discoveries, Inc

For direct contact, visit the study record on ClinicalTrials.gov .